ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma.

Abstract

BACKGROUND:

Selective internal radiation therapy (SIRT) is an innovative treatment of hepatocellular carcinoma (HCC). The albumin-bilirubin (ALBI) score was designed to better evaluate liver functions in HCC.

METHODS:

We studied, retrospectively, data from patients treated with SIRT for HCC. The primary endpoint was the occurrence of radioembolization-induced liver disease (REILD). The secondary endpoint was overall survival (OS).

RESULTS:

222 patients were studied. The ALBI grade 1 patients had significantly less REILD (3.4%) after the first SIRT than ALBI grade 2 or 3 patients (16.8%, p = 0.002). Of the 207 patients with data, 77 (37.2%) had a worsening of ALBI grade after one SIRT. The baseline ALBI grade was significantly associated with OS (p = 0.001), also in the multivariable analysis. The ALBI grade after the first SIRT was significantly associated with OS (p ≤ 0.001), with median OS of 26.4 months (CI 95% 18.2-34.7) for ALBI grade 1 patients (n = 48) versus 17.3 months (CI 95% 12.9-21.8) for ALBI grade 2 patients (n = 123) and 8.1 months (CI 95% 4.1-12.1) for ALBI grade 3 patients (n = 36).

CONCLUSIONS:

The baseline ALBI grade is a strong predictor of REILD. The baseline ALBI score and variations of ALBI are prognostic after SIRT.

• Authors: Céline Lescure, Florian Estrade, Maud Pedrono, Boris Campillo-Gimenez, Samuel Le Sourd, Marc Pracht, Xavier Palard, Héloïse Bourien, Léa Muzellec, Thomas Uguen, Yan Rolland, Etienne Garin, Julien Edeline
• Journal: Cancers (Cancers (Basel)) Vol. 13 Issue 15 (Jul 28 2021) ISSN: 2072-6694 [Print] Switzerland
• PMID: 34359695 (Publication Type: Journal Article)